Insmed is a clinical-stage company that discovers, develops, and seeks to commercialize novel, targeted therapies to treat serious rare diseases. The company is developing ALIS, its lead product candidate, for the treatment of nontuberculous mycobacterial lung infection (NTM) and chronic Pseudomonas aeruginosa in non-CF bronchiectasis. ALIS is an inhaled liposomal form of FDA-approved amikacin. In September 2017, INSM reported positive top-line data from their CONVERT pivotal Phase 3 study of ALIS in adult patients with treatment-refractory NTM lung disease caused by Mycobacterium Avium Complex (MAC).
NTM lung disease is associated with increased rates of morbidity and mortality, and MAC is the predominant pathogenic species in NTM lung disease in the United States, Japan, and Europe. The prevalence of NTM lung disease has increased over the past two decades, and is an emerging public health concern worldwide. Researchers have found that the prevalence of NTM in the US was increasing at approximately 8% per year and that NTM patients on Medicare over the age of 65 were 40% more likely to die over the period of the study than those who did not have the disease.
Foresite Capital believes that INSM’s ALIS has the potential to play a significant role in the treatment of NTM lung disease caused by MAC.